Table 3.
Ellipta™ dry powder inhaler correct use, ease of use, and remaining dose determination (3-month placebo-controlled studies, 114417/114418; ITT population)
| Response | Total, n (%) N=655a | |
|---|---|---|
| Day 1 | ||
| Used correctly | n | 632 |
| Yes | 618 (98) | |
| No | 14 (2) | |
| Missing | 0 | |
| Day 2 | ||
| Used correctly | n | 629 |
| Yes | 625 (>99) | |
| No | 4 (<1) | |
| Missing | 0 | |
| Week 6 | ||
| Used correctly | n | 587 |
| Yes | 580 (99) | |
| No | 6 (1) | |
| Missing | 1 (<1) | |
| Ease of use rating | n | 587 |
| Very easy | 433 (74) | |
| Easy | 147 (25) | |
| Neutral | 6 (1) | |
| Difficult | 1 (<1) | |
| Ease of telling how many doses left | n | 587 |
| Very easy | 471 (80) | |
| Easy | 111 (19) | |
| Neutral | 3 (<1) | |
| Difficult | 2 (<1) | |
Notes:
a
About 22 patients from Canada were excluded from these analyses, as they were not included in the inhaler preference part of the studies; one patient was randomized but did not receive study treatment or take part in the test. N is the number of patients in the total population; n is the number of patients with analyzable data at the current time point.
Abbreviation: ITT, intent-to-treat.